- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00001887
Factors Involved in Asthma and Airway Inflammation
The Role of a Novel Aminopeptidase-Like Protein in Asthma
Asthma is the third leading cause of preventable admissions to the hospital in the United States. Deaths and diseases associated with asthma increase every year. Asthma is a disorder of airway inflammation. There are several factors thought to play a role in the process of inflammation.
In this study researchers are particularly interested in studying a factors known as TNF (tumor necrosis factor) and the sites where this factor attaches called receptors. Another factor associated with receptor processing is called aminopeptidase-like protein. It may be involved in the relationship between TNF, it's receptors, and inflammation.
In order to understand the relationship between these factors, researchers plan to simulate an allergic reaction in the lungs and airways of patients participating in the study. By doing this they can collect and study the factors causing airway inflammation. Samples collected from patients with asthma will be compared to samples from volunteers without asthma.
Patients and volunteers participating in this study will not directly benefit from this research. However, the study may help researchers understand the causes and processes involved in asthma. In addition, the study may lead to the development of new treatments for asthma and airway inflammation.
Study Overview
Detailed Description
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Heart, Lung and Blood Institute (NHLBI)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
ASTHMATICS:
Must be between 18 and 65 years of age, male or female, and must be at least 5 feet in height.
The diagnosis of asthma requires a history of intermittent, reversible expiratory flow limitation. Patients will have mild-to-moderately severe asthma as defined by a baseline forced expiratory flow in one second (FEV(1)) greater than 70% of predicted (at least 6 hours after bronchodilator use) and therapy limited to inhaled beta-agonists.
Positive skin prick-puncture test to one or more common aeroallergens.
A positive inhaled methacholine challenge as defined by a decrease in FEV(1) of at least 20% (PC(20)) in response to inhalation of less than 25 mg/ml of methacholine.
A decrease in FEV(1) of at least 20% in response to inhalation of up to 10,000 bioequivalency allergy units (BAU) or allergy units (AU) per ml of a selected common aeroallergen (house dust mite, cat hair or grasses) or up to 150 Antigen E units per ml of short ragweed. Asthmatic patients must also demonstrate a late asthmatic response (defined as a 20% fall from the baseline established following completion of the early asthmatic response).
Normal complete blood count, PT, PTT, and serum electrolytes, mineral and hepatic panels (less than 30 ml of blood will be drawn), normal EKG and chest radiograph without acute pulmonary infiltrates.
Women of childbearing potential must have a negative pregnancy test within 2 weeks prior to study and willingness to adhere to reliable birth control methods during the study.
Must not have a diagnosis of a pulmonary disorder other than asthma (e.g., chronic bronchitis, cystic fibrosis, bronchiectasis, HIV-related lymphocytic airway inflammation).
Must not have a baseline FEV(1) of less than 70% predicted.
Must not have respiratory tract infection or asthma exacerbation within 4 weeks of screening.
Must not use theophylline, oral or inhaled corticosteroids, nedocromil sodium, cromolyn sodium, zilueton, leukotriene receptor antagonists (e.g., zafirlukast or montelukast), or anti-cholinergic agents within the prior 3 months. In addition, patients requiring ongoing therapy with anti-histamines, hydroxyzine, and tricyclic anti-depressants will be excluded. Research subjects can continue therapy with inhaled beta-agonists during the study.
No history of anaphylaxis or severe allergic response.
No history of adverse reactions to lidocaine or other local anesthetics.
No history of active inhaled or intravenous drug abuse or alcohol abuse.
Must not have an abnormal EKG or evidence of coronary artery disease.
Must not require chronic anti-coagulant therapy.
Must not use aspirin within 2 weeks of the bronchoscopic study or non-steroidal anti-inflammatory agents within 2 days of the bronchoscopic study.
No history of cigarette smoking within the past 3 years.
No history of allergy immunotherapy within the past year.
Not allergic to methacholine.
PT or PTT must not be prolonged 2 seconds greater than normal range.
Platelet count must be greater than or equal to 150,000/mm(3).
Must not test positive for human immunodeficiency virus.
RESEARCH VOLUNTEERS:
Must be between 18 and 65 years of age, male or female, and must be at least 5 feet in height.
A negative inhaled methacholine challenge as defined by the absence of a decrease in FEV(1) by 20% (PC(20)) in response to inhalation of 25 mg/ml of methacholine.
A negative skin test to a panel of common aeroallergens.
Normal complete blood count, PT, PTT, and serum electrolytes, mineral and hepatic panels (less than 30 ml of blood will be drawn). Negative hepatitis serology. Normal EKG and chest radiograph without acute pulmonary infiltrates.
Women of childbearing potential must have a negative pregnancy test within 2 weeks prior to study and willingness to adhere to reliable birth control methods during the study.
No history of asthma, allergic rhinitis, or atopic dermatitis.
Must not have a diagnosis of a pulmonary disorder other than asthma (e.g., chronic bronchitis, cystic fibrosis, bronchiectasis, HIV-related lymphocytic airway inflammation).
Must not have a baseline FEV(1) of less than 70% predicted.
Must not have respiratory tract infection or asthma exacerbation within 4 weeks of screening.
Must not use theophylline, oral or inhaled corticosteroids, nedocromil sodium, cromolyn sodium, zilueton, leukotriene receptor antagonists (e.g., zafirlukast or montelukast), or anti-cholinergic agents within the prior 3 months. In addition, patients requiring ongoing therapy with anti-histamines, hydroxyzine, and tricyclic anti-depressants will be excluded. Research subjects can continue therapy with inhaled beta-agonists during the study.
No history of anaphylaxis or severe allergic response.
No history of adverse reactions to lidocaine or other local anesthetics.
No history of active inhaled or intravenous drug abuse or alcohol abuse.
Must not have an abnormal EKG or evidence of coronary artery disease.
Must not require chronic anti-coagulant therapy.
Must not use aspirin within 2 weeks of the bronchoscopic study or non-steroidal anti-inflammatory agents within 2 days of the bronchoscopic study.
No history of cigarette smoking within the past 3 years.
No history of allergy immunotherapy within the past year.
Not allergic to methacholine.
PT or PTT must not be prolonged 2 seconds greater than normal range.
Platelet count must be greater than or equal to 150,000/mm(3).
Must not test positive for human immunodeficiency virus.
Study Plan
How is the study designed?
Collaborators and Investigators
Publications and helpful links
General Publications
- Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997 Sep;156(3 Pt 1):787-93. doi: 10.1164/ajrccm.156.3.9611072.
- Pappas G, Hadden WC, Kozak LJ, Fisher GF. Potentially avoidable hospitalizations: inequalities in rates between US socioeconomic groups. Am J Public Health. 1997 May;87(5):811-6. doi: 10.2105/ajph.87.5.811.
- Azzawi M, Bradley B, Jeffery PK, Frew AJ, Wardlaw AJ, Knowles G, Assoufi B, Collins JV, Durham S, Kay AB. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am Rev Respir Dis. 1990 Dec;142(6 Pt 1):1407-13. doi: 10.1164/ajrccm/142.6_Pt_1.1407.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 990075
- 99-H-0075
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet